Strong Sales Growth in Q1 FY2024 (April to June 2023)

NZX/ASX Announcement

15 August 2023

Strong Sales growth in Q1 FY2024 (April to June 2023)

Highlights

• TruScreen experiences strong sales growth in Q1 FY24
• Product sales up 100% Q1 2024/Q1 2023 and SUS sales up 73% to 56,160 units for the quarter
• China continues to grow strongly with contributions from new Health Check sector

Truscreen Group Limited (NZX/ASX:TRU) is pleased to report a 100% growth in sales over the same quarter year on year and a 73% growth in sales of Single Use Sensor (SUS) for the same period.

China continues to drive the growth, and demand is returning to pre COVID levels. The commencement of the Health Check project which aims to screen 10,000 women in the next 3 years also contributed to the sales growth.

The endorsement of TruScreen's AI-enabled technology in the latest edition of CSCCP's China Cervical Cancer Screening Guideline, published in the July 2023 edition of CSCCP's journal, Chinese Journal of Clinical Gynaecology and Obstetrics, and the recent endorsement in the prestigious Blue Book in China, are enabling our distributor Siweixiangtai Tech Co. Ltd (SWXT) to capitalise on the rapid growth in demand.

The CEO, Dr Beata Edling commented:
“I am delighted to report on our Q1 results. A recent trip to Asia and Eastern Europe has confirmed that our efforts in co-investing with our committed distributors are paying off and that the distributors are poised to capture the rapid growth in demand for TruScreen’s technology.

We have invested considerable resources in developing Vietnam, Saudi Arabia and Zimbabwe, and expect that our distributors will broaden our installed base of TruScreen business in their regions in the coming years”.

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:




Dr Beata Edling
Chief Executive Officer
[email protected]
Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF